Physician profile
Michael Arcuri
NPI 1356607642
$8,155.02
in general payments reported to CMS, 2019-2025
53 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $955 · 2021: $1,273 · 2022: $1,116 · 2023: $1,300 · 2024: $1,304 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.21 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,292.77 | 2021-2025 | Vraylar, Linzess, Ubrelvy |
| Lilly USA, LLC | $1,025.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $719.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $566.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $418.83 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $382.08 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.58 | 2019-2024 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals Lp | $342.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $334.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.15 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $252.84 | 2019-2022 | |
| Allergan, INC. | $174.02 | 2019-2020 | |
| Astellas Pharma US INC | $149.42 | 2021-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $142.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.72 | 2022-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Arcuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.